Effects of beetroot juice on exercise performance in patients with lung disease
The Effects of Dietary Nitrate Supplementation on Exercise Tolerance in Patients With Fibrotic Interstitial Lung Disease
This study is testing if drinking beetroot juice can help people with lung disease exercise better and improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | University of British Columbia Academic / other |
| Drugs / interventions | prednisone |
| Locations | 2 sites (Vancouver, British Columbia and 1 other locations) |
| Trial ID | NCT04299945 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of drinking nitrate-rich beetroot juice on exercise performance in patients with fibrotic interstitial lung disease (ILD). Participants will consume either concentrated beetroot juice or a placebo with trace amounts of nitrate, and their submaximal cycle exercise endurance will be measured. The goal is to determine if dietary nitrate supplementation can enhance exercise capacity and improve quality of life for individuals suffering from ILD. The study aims to fill a gap in understanding optimal exercise training methods for this patient population.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with idiopathic pulmonary fibrosis, idiopathic fibrotic nonspecific interstitial pneumonia, chronic hypersensitivity pneumonitis, or unclassifiable ILD who are clinically stable.
Not a fit: Patients with significant cardiovascular, musculoskeletal, or neurological diseases that contraindicate exercise testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved exercise performance and quality of life for patients with fibrotic interstitial lung disease.
How similar studies have performed: While the effects of beetroot juice on exercise performance have been studied in other populations, this specific application in patients with fibrotic interstitial lung disease is novel and has not been previously tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses * Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis * Oxygen saturation ≥92% by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks * Can fluently read and write in English Exclusion Criteria: * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) (see Table 4 from ERS/ATS consensus statement) * Other significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * FVC \<50% or DLCO \<25% * Use of prednisone \>10 mg/day for \>2 weeks within 3 months of the first study visit * Cardiac pacemaker or any metal or electronics inside of the body
Where this trial is running
Vancouver, British Columbia and 1 other locations
- Providence Health Care - St. Paul's Hosptial — Vancouver, British Columbia, Canada (Recruiting)
- Vancouver Coastal Health — Vancouver, Canada (Recruiting)
Study contacts
- Study coordinator: Olivia Ferguson, MSc
- Email: Olivia.Ferguson@hli.ubc.ca
- Phone: 604-806-8835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.